Modality
Radioligand
MOA
CGRPant
Target
CD38
Pathway
Proteasome
MDD
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
Dec 2019
→ Dec 2031
Phase 2Current
NCT08958144
2,137 pts·MDD
2019-12→2031-12·Completed
NCT04272871
1,384 pts·MDD
2022-10→TBD·Recruiting
3,521 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-235.7y awayPh2 Data· MDD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2031-12-23 · 5.7y away
MDD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08958144 | Phase 2 | MDD | Completed | 2137 | HbA1c |
| NCT04272871 | Phase 2 | MDD | Recruiting | 1384 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα |